Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

Treatment of PAF With the Synaptic System

NCT05905835 · View on ClinicalTrials.gov ↗

Study Summary

Enrolled subjects will be treated with the Synaptic Cryoablation System. Treatment will include cryoablation of the pulmonary veins to achieve PVI. All subjects will be followed for twelve (12) months after completion of the index ablation procedure.

Interventions

  • DEVICE Synaptic Cryoablation System

Study Locations (10)

Arizona

  • Banner University Medical Center — Phoenix
  • Dignity Health Arizona Research Enterprise — Phoenix

California

  • Cedars-Sinai Medical Center — Los Angeles
  • Mercy General Hospital — Sacramento

Arkansas

  • St. Bernard's Heart & Vascular — Jonesboro

Missouri

  • St. Luke's Mid America — Kansas City

New York

  • Northwell Health - Lenox Hill Hospital — New York

Tennessee

  • Vanderbilt University Medical Center — Nashville

Texas

  • Christus Health Frances Hospital — Tyler

Virginia

  • VCU Pauley Heart Center — Richmond

Trial Details

FieldValue
Enrollment Target 128 participants
Start Date 2023-09-20
Est. Completion 2025-12-05
Phase NA

Sponsor

Synaptic Medical Corporation

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05905835

The ClinicalTrials.gov registry entry for NCT05905835 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Synaptic Medical Corporation, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Paroxysmal Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention — of which Synaptic Cryoablation System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05905835 reports 10 study locations spanning 8 distinct geographic areas — top geographies include Arizona, California, Arkansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05905835 about?

NCT05905835 is a clinical study titled "Treatment of PAF With the Synaptic System". Enrolled subjects will be treated with the Synaptic Cryoablation System. Treatment will include cryoablation of the pulmonary veins to achieve PVI. All subjects will be followed for twelve (12) months after completion of the index ablation procedure.

What is the current status of trial NCT05905835?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 128 participants. The study started on 2023-09-20. Estimated completion is 2025-12-05.

What conditions does trial NCT05905835 study?

This clinical trial studies the following conditions: Paroxysmal Atrial Fibrillation. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05905835?

The interventions under investigation include: Synaptic Cryoablation System (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05905835?

This trial is sponsored by Synaptic Medical Corporation, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05905835 being conducted?

This trial has 10 study locations across Arizona, Arkansas, California, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial